Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.70 |
| ▸ | BCR | P11274 | 7/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.69 |
| ▸ | KIT | P10721 | 5/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.68 |
| ▸ | PRKCA | P17252 | 3/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | LYN | P07948 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.62 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | ITK | Q08881 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653881 | 0.89 | ABL1 (0.72) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL1929333 | 0.89 | ABL1 (0.65) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL29707254 | 0.88 | ABL1 (0.71) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL533540 | 0.88 | ABL1 (0.71) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL12715062 | 0.88 | ABL1 (0.77) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL6176992 | 0.88 | PDGFRA (0.66) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL1654172 | 0.88 | PDGFRA (0.79) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL28747993 | 0.88 | ABL1 (0.63) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL1566674 | 0.87 | ABL1 (0.69) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL13531218 | 0.87 | ABL1 (0.69) | ABL1BCRPDGFRAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268850-B2 | Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | disclosed |
| US-8268850-B2 | Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | disclosed |
| US-8268850-B2 | Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | disclosed |
| EP-2148874-B1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2012-02-08 | — | — | EP | disclosed |
| EP-2148874-B1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2012-02-08 | — | — | EP | disclosed |
| US-20100190811-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-07-29 | — | — | US | disclosed |
| US-20100190811-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-07-29 | — | — | US | disclosed |
| US-20100190811-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-07-29 | — | — | US | disclosed |
| EP-2148874-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009109991-A2 | NOVEL HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD., (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109991-A2 | NOVEL HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD., (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008137605-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190811-A1 | PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | ABL1 21/4885BCR 169/4885PDGFRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.